Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Pulmonary Embolism, Splanchnic Vein Thrombosis
Conditions
Brief summary
This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related venous thrombosis in cancer patients who have completed anticoagulation therapy. Apixaban may help in prevention by blocking some of the enzymes needed for venous thrombosis.
Detailed description
PRIMARY OBJECTIVE: I. Any episode of major bleeding including fatal bleeding or clinically relevant non-major bleeding. SECONDARY OBJECTIVES: I. The proportion of patients who experienced at least one such bleeding event within 6 months of beginning treatment. II. Venous thromboembolism (VTE) recurrence including deep vein thrombosis (DVT), pulmonary embolism (PE), fatal PE, or arterial thromboembolism. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients receive lower dose apixaban orally (PO) twice daily (BID) for 365 days. GROUP II: Patients receive higher dose apixaban PO BID for 365 days. After completion of study treatment, patients are followed up for 30 days.
Interventions
DRUGApixaban
Given PO
Sponsors
National Cancer Institute (NCI)
Academic and Community Cancer Research United
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed acute index (original venous thrombotic) event: lower extremity or upper extremity (jugular, innominate, subclavian, axillary, brachial) DVT, PE, splanchnic (hepatic, portal, splenic, mesenteric, renal, gonadal), or cerebral vein thrombosis for which the patient has received \>= 180 days (but =\< 365 days) of anticoagulant therapy prior to registration; the date, imaging modality, and location of index event will be required; the date of initiation and specific type of anticoagulants used will also be required * Active cancer defined as metastatic disease and/or any evidence of cancer on cross-sectional or positron emission tomography (PET) imaging, cancer related surgery, chemotherapy or radiation therapy within the past 6 months; Note: non-melanoma skin cancer does not meet the cancer requirement * Life expectancy \>= 6 months * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 * Hemoglobin \>= 8 g/dL obtained =\< 30 days prior to registration * Platelet count \>= 50,000/mm\^3 obtained =\< 30 days prior to registration * Alanine aminotransferase (ALT) or aspartate transaminase (AST) =\< 3 x upper limit of normal (ULN) obtained =\< 30 days prior to registration * Calculated creatinine clearance must be \>= 30 ml/min using the Cockcroft-Gault formula obtained =\< 30 days prior to registration * Negative serum or urine pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only; * Note: a woman of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal; menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes * Ability to provide informed written consent * Willing to undergo monthly follow-up assessment, either in person at the enrolling institution or by telephone
Exclusion criteria
* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception * Note: women of child bearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug (s) plus 33 days after finishing the last dose * Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug (s) plus 93 days after finishing the last dose * Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements; however they must still undergo pregnancy testing as described in this section; note: investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy; investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception; highly effective methods of contraception have a failure rate of \< 1% when used consistently and correctly; at a minimum, subjects must agree to the use of one method of highly effective contraception as listed below: * Male condoms with spermicide * Hormonal methods of contraception including combined oral contraceptive pills, vaginal ring, injectables, implants and intrauterine devices (IUDs) such as Mirena by WOCBP subject or male subject's WOCBP partner * Female partners of male subjects participating in the study may use hormone based contraceptives as one of the acceptable methods of contraception * IUDs, such as ParaGard * Tubal ligation * Vasectomy * Complete abstinence * Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an acceptable form of contraception for all study drugs; acceptable alternate methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinence * Active major bleeding * Severe hypersensitivity reaction to apixaban (e.g., anaphylactic reactions) * Current use of strong CYP3A4 inducers or inhibitors * NOTE: patients may be eligible if they transition to an alternative agent or are able to stop CYP3A4 inducer or inhibitor * Current use of thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) that will be continued on study * Severe liver disease (known cirrhosis Childs Pugh class B or C), or active hepatitis * Documented venous thromboembolism while on therapeutic anticoagulation (anticoagulation failure) * Mechanical heart valve * Documented hemorrhagic tendencies (e.g., hemophilia) * Bacterial endocarditis * Any of the following conditions: * Intracranial bleeding =\< 6 months prior to randomization * Intraocular bleeding =\< 6 months prior to randomization * Gastrointestinal bleeding and/or endoscopically proven ulcer =\< 6 months prior to randomization * Head trauma or major trauma =\< 1 month prior to randomization * Neurosurgery =\< 2 weeks prior to randomization * Major surgery =\< 1 week prior to randomization * Gross hematuria at the time of randomization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CIF of Major or Clinically Relevant Non-major Bleeding Combined With Death as Competing Risk | 12 months | Incidence of major bleeding and clinically relevant non-major bleeding will be estimated using the cumulative incidence function (CIF) with death without major bleeding or clinically relevant non-major bleeding and with adverse events that results in termination of treatment (including vascular events) as competing risks. The time to event is defined as the time from randomization to the first occurrence of a major bleeding, a clinically relevant non-major bleeding, death without major bleeding or clinically relevant non-major bleeding, or an adverse event that results in termination of treatment. Patients who were lost to follow-up, who withdrew informed consent before the end of the predefined study duration will be censored at the last day the patient had a complete assessment for study outcomes within the intended study period. The difference in the incidences of the combined endpoint at 12 months between treatment arms will be estimated along with a 95% confidence interval |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Patients Who Experienced at Least One Bleeding Event | 6 months | Incidence of major bleeding and clinically relevant non-major bleeding will be estimated using the cumulative incidence function (CIF) with death without major bleeding or clinically relevant non-major bleeding and with adverse events that results in termination of treatment (including vascular events) as competing risks. The time to event is defined as the time from randomization to the first occurrence of a major bleeding, a clinically relevant non-major bleeding, death without major bleeding or clinically relevant non-major bleeding, or an adverse event that results in termination of treatment. Patients who were lost to follow-up, who withdrew informed consent before the end of the predefined study duration will be censored at the last day the patient had a complete assessment for study outcomes within the intended study period. The difference in the incidences of the combined endpoint at 6 months between treatment arms will be estimated along with a 95% confidence interval. |
| Cumulative Incidence Function of DVT/PE Treating Death or AE Resulting in End of Treatment as Competing Risk by Study Arm | 12 months | For the secondary outcome analysis, the time from starting treatment to the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE) outcome will be analyzed using the same method described in the section for primary outcome plan. For this outcome, death without DVT/PE and adverse events leading to termination of treatment will be treated as the competing risks. |
Countries
United States
Participant flow
Recruitment details
5 patients enrolled in arm 1 and 5 patients enrolled in arm 2 did not begin treatment and therefore are not included in the participant flow table.
Participants by arm
| Arm | Count |
|---|---|
| Group I (2.5mg Dose Apixaban) Patients receive lower dose apixaban PO BID for 365 days.\>
\> Apixaban: Given PO | 179 |
| Group II (5mg Dose Apixaban) Patients receive higher dose apixaban PO BID for 365 days.\>
\> Apixaban: Given PO | 181 |
| Total | 360 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 22 | 22 |
| Overall Study | Alternative Therapy | 0 | 3 |
| Overall Study | Death | 21 | 16 |
| Overall Study | Disease Progression | 2 | 8 |
| Overall Study | Lost to Follow-up | 1 | 1 |
| Overall Study | Other Complicating Disease | 9 | 5 |
| Overall Study | Physician Decision | 2 | 2 |
| Overall Study | Withdrawal by Subject | 11 | 15 |
Baseline characteristics
| Characteristic | Group I (2.5mg Dose Apixaban) | Group II (5mg Dose Apixaban) | Total |
|---|---|---|---|
| Age, Continuous | 63.6 years STANDARD_DEVIATION 10.96 | 64.3 years STANDARD_DEVIATION 10.72 | 64.0 years STANDARD_DEVIATION 10.83 |
| ECOG Performance Status 0 | 97 Participants | 96 Participants | 193 Participants |
| ECOG Performance Status 1 | 73 Participants | 80 Participants | 153 Participants |
| ECOG Performance Status 2 | 9 Participants | 5 Participants | 14 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 5 Participants | 2 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 171 Participants | 176 Participants | 347 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 3 Participants | 3 Participants | 6 Participants |
| Location of Initial Thrombosis Deep-vein thrombosis (including atypical VTE) | 82 Participants | 86 Participants | 168 Participants |
| Location of Initial Thrombosis Pulmonary embolism | 97 Participants | 95 Participants | 192 Participants |
| Primary Tumor Site Brain/CNS | 3 Participants | 5 Participants | 8 Participants |
| Primary Tumor Site Breast | 10 Participants | 25 Participants | 35 Participants |
| Primary Tumor Site Colon/rectum/pancreas/stomach | 44 Participants | 45 Participants | 89 Participants |
| Primary Tumor Site ENT | 0 Participants | 1 Participants | 1 Participants |
| Primary Tumor Site Genitourinary | 0 Participants | 3 Participants | 3 Participants |
| Primary Tumor Site Gynecologic | 19 Participants | 17 Participants | 36 Participants |
| Primary Tumor Site Kidney/bladder | 8 Participants | 9 Participants | 17 Participants |
| Primary Tumor Site Liver/bile duct | 6 Participants | 3 Participants | 9 Participants |
| Primary Tumor Site Lung/bronchus | 26 Participants | 17 Participants | 43 Participants |
| Primary Tumor Site Lymphoma/Myeloma/Leukemia | 34 Participants | 16 Participants | 50 Participants |
| Primary Tumor Site Melanoma | 1 Participants | 0 Participants | 1 Participants |
| Primary Tumor Site Other | 4 Participants | 3 Participants | 7 Participants |
| Primary Tumor Site Prostate | 5 Participants | 6 Participants | 11 Participants |
| Primary Tumor Site Sarcoma | 5 Participants | 4 Participants | 9 Participants |
| Primary Tumor Site Skin | 1 Participants | 3 Participants | 4 Participants |
| Primary Tumor Site Thyroid | 2 Participants | 3 Participants | 5 Participants |
| Primary Tumor Site Tongue/mouth/pharynx | 0 Participants | 2 Participants | 2 Participants |
| Primary Tumor Site Upper Gastrointestinal | 3 Participants | 2 Participants | 5 Participants |
| Primary Tumor Site Uterine cervix/corpus | 8 Participants | 17 Participants | 25 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 7 Participants | 9 Participants | 16 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) White | 168 Participants | 169 Participants | 337 Participants |
| Region of Enrollment United States | 179 participants | 181 participants | 360 participants |
| Sex: Female, Male Female | 92 Participants | 107 Participants | 199 Participants |
| Sex: Female, Male Male | 87 Participants | 74 Participants | 161 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 26 / 179 | 22 / 181 |
| other Total, other adverse events | 93 / 179 | 75 / 181 |
| serious Total, serious adverse events | 70 / 179 | 69 / 181 |
Outcome results
Primary
CIF of Major or Clinically Relevant Non-major Bleeding Combined With Death as Competing Risk
Incidence of major bleeding and clinically relevant non-major bleeding will be estimated using the cumulative incidence function (CIF) with death without major bleeding or clinically relevant non-major bleeding and with adverse events that results in termination of treatment (including vascular events) as competing risks. The time to event is defined as the time from randomization to the first occurrence of a major bleeding, a clinically relevant non-major bleeding, death without major bleeding or clinically relevant non-major bleeding, or an adverse event that results in termination of treatment. Patients who were lost to follow-up, who withdrew informed consent before the end of the predefined study duration will be censored at the last day the patient had a complete assessment for study outcomes within the intended study period. The difference in the incidences of the combined endpoint at 12 months between treatment arms will be estimated along with a 95% confidence interval
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group I (2.5mg Dose Apixaban) | CIF of Major or Clinically Relevant Non-major Bleeding Combined With Death as Competing Risk | 9.6 proportion of participants |
| Group II (5mg Dose Apixaban) | CIF of Major or Clinically Relevant Non-major Bleeding Combined With Death as Competing Risk | 13.5 proportion of participants |
p-value: 0.311795% CI: [0.38, 1.37]Gray Test P-value
Secondary
Cumulative Incidence Function of DVT/PE Treating Death or AE Resulting in End of Treatment as Competing Risk by Study Arm
For the secondary outcome analysis, the time from starting treatment to the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE) outcome will be analyzed using the same method described in the section for primary outcome plan. For this outcome, death without DVT/PE and adverse events leading to termination of treatment will be treated as the competing risks.
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group I (2.5mg Dose Apixaban) | Cumulative Incidence Function of DVT/PE Treating Death or AE Resulting in End of Treatment as Competing Risk by Study Arm | 5.8 proportion of participants |
| Group II (5mg Dose Apixaban) | Cumulative Incidence Function of DVT/PE Treating Death or AE Resulting in End of Treatment as Competing Risk by Study Arm | 7.1 proportion of participants |
Secondary
Proportion of Patients Who Experienced at Least One Bleeding Event
Incidence of major bleeding and clinically relevant non-major bleeding will be estimated using the cumulative incidence function (CIF) with death without major bleeding or clinically relevant non-major bleeding and with adverse events that results in termination of treatment (including vascular events) as competing risks. The time to event is defined as the time from randomization to the first occurrence of a major bleeding, a clinically relevant non-major bleeding, death without major bleeding or clinically relevant non-major bleeding, or an adverse event that results in termination of treatment. Patients who were lost to follow-up, who withdrew informed consent before the end of the predefined study duration will be censored at the last day the patient had a complete assessment for study outcomes within the intended study period. The difference in the incidences of the combined endpoint at 6 months between treatment arms will be estimated along with a 95% confidence interval.
Time frame: 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group I (2.5mg Dose Apixaban) | Proportion of Patients Who Experienced at Least One Bleeding Event | 4.9 proportion of participants |
| Group II (5mg Dose Apixaban) | Proportion of Patients Who Experienced at Least One Bleeding Event | 5.8 proportion of participants |
p-value: 0.99795% CI: [0.4, 2.53]Gray Test P-value